BiotechTube
All Reports
👁️

Ophthalmology

Competitive landscape report · 22 products · 11 companies

Executive Summary

The ophthalmology landscape features 22 products in active development across 11 companies. The space remains highly competitive with significant activity across all clinical stages.

3 products are currently in Phase 3 trials, 9 in Phase 2, and 4 in Phase 1. Leading companies by pipeline count include Clearside Biomedical, Unity Biotechnology, Tarsus Pharmaceuticals.

4 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
Lotilaner ophthalmic solution, 0.25% + Vehicle controlDemodex Blepharitis
Tarsus Pharmaceuticals
Approved
80
2
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Glaucoma, Open-Angle
Mankind Pharma
Phase 3
77
3
FYB203 2 mg (0.05 mL of 40 mg/mL)Age-Related Macular Degeneration
Formycon AG
Approved
77
4
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Age-Related Macular Degeneration
Formycon AG
Approved
77
5
Latanoprost plus adjunctive glaucoma medicationPrimary Open Angle Glaucoma
Sight Sciences
Approved
77
6
CT-P42 + EyleaDiabetic Macular Edema (DME)
Celltrion
Phase 3
77
7
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinMacular Edema
Clearside Biomedical
Phase 3
69
8
KVD001 InjectionDiabetic Macular Edema
KalVista Pharmaceuticals
Phase 2
47
9
IVT aflibercept + Sham SC + SC CLS-TADiabetic Macular Edema
Clearside Biomedical
Phase 2
44
10
4 mg CLS-TA + Sham + IVT afliberceptMacular Edema
Clearside Biomedical
Phase 2
44

Top Companies by Pipeline Count

1Clearside Biomedical5 products2Unity Biotechnology4 products3Tarsus Pharmaceuticals2 products4KalVista Pharmaceuticals2 products5Formycon AG2 products6Sight Sciences2 products7Alteogen1 products8Mankind Pharma1 products9OKYO Pharma1 products10Skye Bioscience1 products

Phase Distribution

Pre-clinical
1
Phase 1
4
Phase 1/2
1
Phase 2
9
Phase 3
3
Approved
4

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports